Advertisement

Topics

Clinical Trials About "AIN457 AIN457 AIN457 Placebo infectious Uveitis" RSS

08:19 EST 20th November 2018 | BioPortfolio

We list hundreds of Clinical Trials about "AIN457 AIN457 AIN457 Placebo infectious Uveitis" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "AIN457 AIN457 AIN457 Placebo infectious Uveitis" on BioPortfolio

We have published hundreds of AIN457 AIN457 AIN457 Placebo infectious Uveitis news stories on BioPortfolio along with dozens of AIN457 AIN457 AIN457 Placebo infectious Uveitis Clinical Trials and PubMed Articles about AIN457 AIN457 AIN457 Placebo infectious Uveitis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AIN457 AIN457 AIN457 Placebo infectious Uveitis Companies in our database. You can also find out about relevant AIN457 AIN457 AIN457 Placebo infectious Uveitis Drugs and Medications on this site too.

Showing "AIN457 AIN457 AIN457 Placebo infectious Uveitis" Clinical Trials 1–25 of 19,000+

Extremely Relevant

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.


Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis

This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.

Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis

The purpose of the extension study is to provide patients completing the 28-week core study with an opportunity to receive an additional 22 weeks of continuous treatment.


Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis Study

The extension study will serve to provide patients completing the 24 week core study with an opportunity to receive additional 26 weeks of continuous treatment. It will also provide 12-week treatment-free safety follow up for patients who will not receive continuous treatment in extension.

Efficacy of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis

This study is designed as a proof of concept of AIN457 in patients with ankylosing spondylitis. The study will address the evaluation of the efficacy at 6 and up to 28 weeks after two doses of AIN457 administered three weeks apart In Part 1 patients will be administered either AIN457 10 mg/kg or placebo. In Part 2, patients will be administered either 10 mg/kg, 1.0 mg/kg or 0.1 mg/kg AIN457. Thirty patients will be enrolled in Part 1 and an additional 30 patients into Part 2...

Safety and Efficacy of AIN457 in Behçet's Patients With Posterior or Panuveitis

The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to Behçet's disease during the 24 weeks of study therapy as compared to standard of care alone.

Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)

This study will assess at Week 16 the efficacy and safety of AIN457 at different doses in patients with active RA despite stable MTX therapy. Treatment will continue up to Week 48 with a safety follow-up at Week 60 to assess the long term efficacy and safety of AIN457 treatment in combination with MTX in RA.

Safety and Efficacy of AIN457 in Behçet's Patients With Posterior or Panuveitis

The purpose of this extension trial is to provide patients with an opportunity to receive an additional 26 weeks of treatment yielding safety and efficacy data for AIN457 in Behçet's patients with intermediate, posterior or panuveitis and to provide a 12 week treatment-free safety follow up period.

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis

The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body area is affected by the disease (compared to placebo).

Double Blind, Placebo-Controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients

Evaluate the safety, tolerability and pharmacokinetics of AIN457 when administered as a single dose (intravenous infusion) in patients with active rheumatoid arthritis in combination with a stable dose of methotrexate. And to compare efficacy on the dose groups.

Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis

This study is designed as a proof of concept of AIN457 in patients with psoriatic arthritis. The study will address the evaluation of the efficacy at 6 and up to 24 weeks after two doses of AIN457 10 mg/kg administered three weeks apart.

Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma

This study is a preliminary proof of efficacy study of AIN457 in patients with bronchial asthma that is poorly controlled with the current standard of care.

A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis

This is a two-arm, parallel group, double-blind, placebo-controlled proof-of-concept study comparing 3 mg/kg of AIN457 to placebo. Subjects with a diagnosis of moderate to severe stable plaque psoriasis will be randomized to receive either AIN457 or placebo. AIN457 or placebo will be administered by single infusion at baseline and subjects will be observed for up to 26 weeks following the infusion.

Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis

This is an exploratory, 4 arm, parallel group, placebo-controlled study comparing three doses of AIN457 to placebo. Subjects with a diagnosis of moderate to severe chronic plaque psoriasis will be randomized to receive either AIN457 at one of the three doses studied or placebo.

Effect of AIN457 on Ozone-induced Airway Neutrophilia Compared to Placebo and Corticosteroid in Healthy Subjects

This study will assess the ability of AIN457 to attenuate the increase in airway neutrophils that is seen following ozone exposure. Healthy subjects will be treated with AIN457, placebo, or oral corticosteroid and the response to a subsequent ozone exposure will be evaluated.

Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis

This study is designed as an extension study to the proof-of-concept trial CAIN457A2209 in patients with moderate to severe ankylosing spondylitis and aims to provide continuous treatment with AIN457 for patients in the core trial, to obtain safety and tolerability information. The study will address the evaluation of efficacy following doses of 3 mg/kg AIN457 given every 4 weeks over a period initially up to 6 months (Part 1) and based on the risk/benefit balance of AIN457 in...

Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg

The proposed exploratory study aims to understand the in vivo skin distribution properties of subcutaneously (s.c.) administered AIN457 in psoriatic and healthy skin using open flow microperfusion (OFM). The data of this study will help to understand the mode of action of AIN457 in its target tissue. It aims to establish a technique assessing in vivo distribution of AIN457 and its metabolites in human dermal interstitial fluid (ISF) and exploring a potential pharmacodyna...

A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body area is affected by the disease (compared to placebo).

A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab (AIN457) to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylit

The current study will assess the clinical Assessment of SpondyloArthritis international Society (ASAS) 20 response to Secukinumab and evaluate to which extent concomitant nonsteroidal anti-inflammatory drug (NSAID) treatment can be reduced in patients treated with Secukinumab or placebo following an initial run-in phase of stable NSAID therapy. In case of a positive outcome concerning the NSAID reduction this study could trigger the development of a guidance concerning NSAID r...

Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy

This is a randomized, double-blind, placebo-controlled, multi-center, Phase II study of s.c. secukinumab 300 mg in approximately 100 randomized patients with overuse rotator-cuff tendinopathy without systemic inflammatory disease

Effect of Multiple Infusions of AIN457 on Disease Activity in Relapsing-remitting Multiple Sclerosis

This study will assess the effect of AIN457 to reduce disease activity in patients with relapsing-remitting multiple sclerosis.

Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease

This study will assess the safety and efficacy of AIN457 in patients with moderate to severe active Crohn's disease.

AIN457 Regimen Finding Extension Study in Patients With Moderate to Severe Psoriasis

The purpose of this study is to provide long term clinical data for the compound for the treatment of the indication of moderate to severe chronic plaque-type psoriasis.

Study of the Efficacy and Safety of Secukinumab in Patients With Active Psoriatic Arthritis With Axial Skeleton Involvement

The purpose of this study is to demonstrate the efficacy and safety of secukinumab 150 mg or 300 mg in the management of axial manifestations in PsA patients who have failed to respond to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) over a 4-week period, according to assessment of spondyloarthritis international society (ASAS) recommendations for the treatment of axial spondyloarthritis (AxSpA).

SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis

The purpose of the study is to evaluate the efficacy and safety of secukinumab 150 mg compared to placebo in the early management (Baseline to Week 8) of spinal pain, disease activity, fatigue and predictability of disease flares in patients with axial spondyloarthritis who have an inadequate response to prior non-steroidal anti-inflammatory drugs. This study will also assess the efficacy and safety of secukinumab 300 mg compared to secukinumab 150 mg from Week 8 to Week 24 in ...


More From BioPortfolio on "AIN457 AIN457 AIN457 Placebo infectious Uveitis"

Advertisement
Quick Search
Advertisement
Advertisement